/Moderna%20Inc%20HQ-by%20hapabapa%20via%20iStock.jpg)
Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage pharmaceutical company. It focuses on discovering and developing messenger RNA (mRNA) based therapies and vaccines for the treatment of autoimmune conditions, infectious, immuno-oncology, rare, and cardiovascular diseases.
Moderna has significantly underperformed the broader market over the past year. MRNA stock has tanked 63.4% over the past 52 weeks and 15.9% on a YTD basis, compared to the S&P 500 Index’s ($SPX) 22.6% surge over the past year and 3.1% gains in 2025.